> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Wins EU Approval For Klygefa, Adding A Weekly Self-Injection Option
- URL: https://www.bullished.co/astrazeneca-wins-eu-approval-for-klygefa-adding-a-weekly-self-injection-option-15b39365/
- Published: 2026-11-16T11:56:57.000Z
- Updated: 2026-11-16T11:56:57.000Z
- Description: The rare-disease treatment improved patients’ daily activities versus placebo, with benefits starting in week one.
- Author: Matteo Parrino
- Tags: SEC Filings, AZN, Industry: Healthcare

[AstraZeneca](https://www.bullished.co/tag/azn/), which develops and sells prescription medicines and vaccines, won [EU approval](https://www.sec.gov/Archives/edgar/data/901832/000165495426009804/a2029d.htm?ref=bullished.co) Monday for Klygefa, a weekly self-injected treatment for adults with generalised myasthenia gravis. The company's announcement said the clearance covers use alongside standard therapy for patients who test positive for anti-acetylcholine receptor antibodies.

## Daily Activities Improved By Week One

The approval rests on a late-stage trial in which Klygefa met its main goal: improving patients' ability to perform daily activities. At week 26, the patient-reported score showed a 1.6-point benefit versus placebo; AstraZeneca said clinically meaningful improvement began in week one and continued through week 26.

The study enrolled 260 patients across 20 countries in North America, Europe, Asia and the Pacific region. Participants received either Klygefa or placebo during a 26-week comparison period. Patients who finished that period could enter an extension study that remains underway.

AstraZeneca said the drug was generally well tolerated and its safety findings were consistent with earlier generalised myasthenia gravis trials of eculizumab and ravulizumab. The findings were presented at the Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine's 2025 Annual Meeting and published in JAMA Neurology.

## An Autoinjector For Severe Muscle Weakness

Generalised myasthenia gravis is an autoimmune disease that weakens muscles. Symptoms can include double vision and slurred speech, and can progress to difficulty swallowing, extreme fatigue and respiratory failure.

AstraZeneca estimates that approximately 66,000 antibody-positive patients live in Germany, France, the UK, Italy and Spain, out of an estimated 82,500 people diagnosed with the disease in those countries.

Klygefa, also called gefurulimab, blocks the immune-system protein C5 and binds to serum albumin, allowing weekly dosing. Patients administer it under the skin with an autoinjector. AstraZeneca described it as the EU's first and only approved dual-binding nanobody C5 inhibitor.

Marc Dunoyer, chief executive of Alexion, AstraZeneca's rare-disease unit, pointed to the flexibility of "[once-weekly, self-administered](https://www.sec.gov/Archives/edgar/data/901832/000165495426009804/a2029d.htm?ref=bullished.co) subcutaneous dosing."

## Rare-Disease Reach Extends Across Markets

The EU decision follows approvals in the US, Japan and other countries for certain adults with the disease. Applications based on the trial remain under review in China and additional countries.

The treatment adds to AstraZeneca's rare-disease business, which includes Soliris and Ultomiris. The Cambridge, UK-based company also sells cancer medicines, including Imfinzi, Tagrisso and Enhertu, alongside treatments for cardiovascular, kidney, metabolic, respiratory and immunological conditions.

AstraZeneca's market value was $286.1 billion at Friday's close.

The EU authorization gives eligible adults a weekly self-injection option alongside their standard treatment.

### Sources

- [Form 6-K — KLYGEFA (GEFURULIMAB) APPROVED IN THE EU](https://www.sec.gov/Archives/edgar/data/901832/000165495426009804/a2029d.htm?ref=bullished.co) — SEC EDGAR
- [AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy](https://finance.yahoo.com/healthcare/articles/astrazeneca-gets-us-nod-expanded-080206700.html?ref=bullished.co) — Reuters

### More on AstraZeneca

- [AstraZeneca Stock Soars 7%, Adding $20 Billion, As Cancer Drugs Lift Quarterly Profit](https://www.bullished.co/astrazeneca-stock-soars-7-adding-20-billion-as-cancer-drugs-lift-quarterly-profit-66c1ed74/)
- [AstraZeneca Core EPS Rises 17% To $2.79 As Cancer Drugs Absorb Farxiga Generic Hit](https://www.bullished.co/astrazeneca-core-eps-rises-17-to-2-79-as-cancer-drugs-absorb-farxiga-generic-hit-8fd6aa21/)
- [Enhertu Wins EU Approval After Surgery, Cutting Recurrence Risk 53% — AstraZeneca Owes Daiichi $75 Million](https://www.bullished.co/enhertu-wins-eu-approval-after-surgery-cutting-recurrence-risk-53-astrazeneca-owes-daiichi-6f920367/)

[All AstraZeneca (AZN) coverage →](https://www.bullished.co/tag/azn/)